ONC — Stock Film
STOCK FILMSCENE 1/11ONC · $317
Stock Expert AI presents
ONC
BeOne Medicines AG
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
BeOne Medicines AG. A quick introduction.

On the stock market since 2016, it operates in the world of health and science. It has 12,000 employees. Now — the numbers.

on the stock market since 2016
12K employees
$34B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $5 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 5%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
99%Products
Products 99%Collaboration 1%
99% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 46% a year over the last 4 years. Red columns mark years that ended in a loss.

$1.2B
2021
$1.4B
2022
$2.5B
2023
$3.8B
2024
$5.3B
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
91
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
94
very strong

Debt is low and cash is strong; the finances stand solid.

VALUATION
62
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
99
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
46
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 21% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 56% a year on average.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $4.5B in the vault; even if every debt were paid off, $2.5B would remain.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $39725% above today’s price.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 118 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 46/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

FINALE · THE GRADE
A
0 / 100 · MoonshotScore

On our five-subject report card, ONC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: ONC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film